{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:44:45Z","timestamp":1772034285175,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clml.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T04:22:42Z","timestamp":1628742162000},"page":"76-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characterization of Second Primary Malignancies in Mucosa-Associated Lymphoid Tissue Lymphomas: A SEER Database Interrogation."],"prefix":"10.1016","volume":"22","author":[{"given":"Sunita","family":"Timilsina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-1915","authenticated-orcid":false,"given":"Aaron","family":"Damato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nibash","family":"Budhathoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3919-3028","authenticated-orcid":false,"given":"Michael L.","family":"Grossbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-7257","authenticated-orcid":false,"given":"Marc","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.08.002_bib0001","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2021.08.002_bib0002","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2021.08.002_bib0003","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.21873\/anticanres.11548","article-title":"Second primary malignancy in bladder carcinoma - a population-based Study","volume":"37","author":"Khanal","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2021.08.002_bib0004","first-page":"4131","article-title":"Second primary malignancy in anal carcinoma\u2013a us population-based study","volume":"35","author":"Shah","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2021.08.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/102656","article-title":"Molecular pathogenesis of MALT lymphoma","volume":"2015","author":"Troppan","year":"2015","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.clml.2021.08.002_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12730","article-title":"Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site","volume":"165","author":"Khalil","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.08.002_bib0007","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/apt.15409","article-title":"Gastric MALT lymphoma in a population-based study in France: clinical features, treatments and survival","volume":"50","author":"Matysiak-Budnik","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clml.2021.08.002_bib0008","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.08.002_bib0009","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1210\/jc.2017-01478","article-title":"Long-term outcomes of 107 cases of primary thyroid mucosa-associated lymphoid tissue lymphoma at a single medical institution in Japan","volume":"103","author":"Watanabe","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clml.2021.08.002_bib0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cam4.2681","article-title":"Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.08.002_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283033","article-title":"Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma","volume":"58","author":"Amiot","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.08.002_bib0012","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/1078-0432.CCR-06-0703","article-title":"Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy","volume":"13","author":"Arcaini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.08.002_bib0013","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00535-013-0844-8","article-title":"Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT)","volume":"49","author":"Tajika","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.clml.2021.08.002_bib0014","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1008328226599","article-title":"Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population","volume":"10","author":"Au","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.08.002_bib0015","series-title":"(SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs excluding AK Research Data, Nov 2018 Sub (2000-2016) <Katrina\/Rita Population Adjustment>- Linked To County Attributes - Total U.S., 1969-2017 Counties","year":"2018"},{"key":"10.1016\/j.clml.2021.08.002_bib0018","unstructured":"Curtis RE and Ries LA:New malignancies among cancer survivors:SEER Cancer Registries,1973-2000, Methodseds Curtis RE,Freedman DM,Ron C, Fies LA, Hacker DG,EDwards BK,Tucker MAand Fraumeni JD Jr.:(National Cancer Institute,Bethesda,MD), 9-14,2006."},{"key":"10.1016\/j.clml.2021.08.002_bib0019","first-page":"1358","article-title":"Multiple primary malignant tumors: A survey of the literature and a statistical study","volume":"16","author":"Warren","year":"1932","journal-title":"Am J Cancer"},{"key":"10.1016\/j.clml.2021.08.002_bib0020","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/1097-0142(197710)40:4+<1892::AID-CNCR2820400820>3.0.CO;2-H","article-title":"Statistical methods for studying multiple primary malignant neoplasms","volume":"40","author":"Schoenberg","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.08.002_bib0021","article-title":"Adverse effects of total body irradiation: a two-decade, single institution analysis","volume":"6","author":"Pearlman","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clml.2021.08.002_bib0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:59Z","timestamp":1761871139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2152265021003281"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Second Primary Malignancies in Mucosa-Associated Lymphoid Tissue Lymphomas: A SEER Database Interrogation.","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}